Grace Therapeutics, Inc. GRCE
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Grace Therapeutics, Inc. (GRCE) is a healthcare company listed in the US with a market value of about $38M.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is financial health (4/5); the weakest is future growth (0/5).
Key numbers: a 5-year average ROIC of -25%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 365% above the current price.
About Grace Therapeutics
Grace Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations. It was profitable in 0 of the last 10 years in our data.
Score: 1.0 / 5
Checks passed
- Price below intrinsic value (DCF, moderate assumptions)
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $100M | $196000 | — | — | — | — |
| Net income | -$8M | -$10M | -$13M | -$42M | -$10M | -$20M | -$26M | -$39M | -$17M | -$8M |
| Free cash flow | — | — | — | -$16M | -$17M | -$14M | -$23M | -$25M | -$10M | -$7M |
| EPS (diluted) | $-0.37 | $-0.45 | $-0.61 | $-2.02 | $-0.47 | $-0.94 | $-1.21 | $-1.87 | $-0.79 | $-0.38 |
| Net margin | — | — | — | — | -9.8% | -10039.8% | — | — | — | — |
| ROIC | -14.2% | -18.8% | -18.2% | -62.2% | -13.5% | -29.4% | -186.0% | -311.5% | -167.7% | -37.0% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 2 analysts is $5.84, 223% above the current price; targets range from $3.88 to $7.80; the consensus rating is “Strong buy”; expected EPS is $-0.76 for the fiscal year ending March 31, 2027.
Frequently asked questions
Is Grace Therapeutics stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 365% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Grace Therapeutics pay a dividend?
Not currently.
Is Grace Therapeutics a good stock to buy?
We do not give buy or sell advice. Grace Therapeutics scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.